Dr. Reddy's Labs

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

FRANKFURT, Germany & HYDERABAD, India--(BUSINESS WIRE)-- #DrReddys--Dr. Reddy's Laboratories enters into definitive agreement to acquire German medical cannabis firm Nimbus Health GmbH.

Dr. Reddy's Laboratories Enters Into Definitive Agreement to Acquire German Medical Cannabis Firm Nimbus Health GmbH

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy's”) announces two major back-to-back recognitions in sustainability and gender equality. Dr. Reddy's is one of seven Indian companies in Bloomberg's Gender-Equality Index (GEI) 2022, and the only Indian pharma company in the index. The 2022 GEI comprises 418 companies across 45 countries with a combined market capitalisation of $16 trillio

Dr. Reddy's Included in S&P Global's Sustainability Yearbook for the 2nd Year and Bloomberg Gender-Equality Index for the 5th Year in a Row

Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.

Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year

Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q3 2022 Results - Earnings Call Transcript

Merck

India-based Dr Reddy's Laboratories Ltd (NYSE: RDY) will launch its generic version of Merck Co & Inc's (NYSE: MRK) COVID-19 antiviral pill, reported Reuters. A company spokesperson said Reddy's would launch the molnupiravir generic at ₹35 ($0.4693) per capsule.

Reddy's To Launch Generic Version Of Merck's COVID-19 Drug At $0.50/Pill: Reuters

Amphastar Pharma

Teva Pharmaceutical

The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.

3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure

HYDERABAD, India--(BUSINESS WIRE)-- #DRREDDY--Prestige BioPharma and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy's”) today announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Prestige BioPharma's proposed biosimilar for the treatment of cancer in select countries in Latin America and Southeast Asia. Prestige BioPharma's proposed biosimilar c

Dr. Reddy's and Prestige BioPharma announce partnership to commercialize biosimilar for cancer treatment in select countries in Latin America and Southeast Asia

SINGAPORE & HYDERABAD, India--(BUSINESS WIRE)-- #DRREDDY--Prestige BioPharma and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy's”) today announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Prestige BioPharma's proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia. Prestige BioPharma's trastuzumab (HD201) is a

Prestige BioPharma and Dr. Reddy's Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries in Latin America and Southeast Asia

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Venlafaxine ER Tablets which is therapeutically equivalent to Venlafaxine Extended-Release Tablets, 150 mg and 225 mg, of Osmotica Pharmaceutical US LLC approved by the U.S. Food and Drug Administration (USFDA). The brand and generic had U.S. sales of approximat

Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Valsartan Tablets, USP, a therapeutic equivalent generic version of Diovan® (valsartan) Tablets approved by the U.S. Food and Drug Administration (USFDA). The Diovan® brand and generic market had U.S. sales of approximately $150 million MAT for the most recent t

Dr. Reddy's Laboratories Announces the Launch of Valsartan Tablets, USP in the U.S. Market

Pfizer

Dr. Reddy's Laboratories Ltd (NYSE: RDY) said it was open to making Pfizer Inc's (NYSE: PFE) COVID-19 antiviral pill, Reuters reported. The new drugs can be used to treat patients once they contract coronavirus infection and are expected to be a substantial market.

Dr. Reddy's Ready To Make COVID-19 Antiviral From Pfizer - Reuters

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2022.

Dr. Reddy's (RDY) Q2 Earnings, Sales Increase Year Over Year

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Ephedrine Sulfate Injection USP, 50 mg/mL, a therapeutic equivalent generic version of Akovaz® (ephedrine sulfate injection) Injection, 50 mg/mL approved by the U.S. Food and Drug Administration (USFDA). The Akovaz® brand and generic market had U.S. sales of app

Dr. Reddy's Laboratories Announces the Launch of Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of REVLIMID® (lenalidomide) Capsules, from

Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU® (carmustine for injection) approved by the U.S. Food and Drug Administration (USFDA). The BiCNU® brand and generic market had U.S. sales of approximately $19.4 million MAT for the

Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market

Aditxt Inc

DUBAI, United Arab Emirates, Oct. 5, 2021 /PRNewswire/ -- AiPharma Global Holdings LLC ("AiPharma") a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases today announced it has entered a binding agreement to sell all of its assets through the sale of one of its wholly owned group subsidaries, to Aditxt Inc. (Nasdaq: ADTX). Aditxt is a biotech innovation company with a mission to improve the health of the immune system.

AiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX). AiPharma Is The Rights Holder Of Antiviral Tablet Avigan / Reeqonus / Qifenda That Has Treated Over 1.5M COVID-19 Patients Since The Outbreak.

Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.

Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy

Citius Pharmaceuticals

CRANFORD, N.J., Sept. 7, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it has entered into a definitive agreement with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd.

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”), announced that it has entered into a definitive agreement with Citius Pharmaceuticals, Inc. (“Citius”) pursuant to which it sold all of its rights to E7777 (an engineered IL-2-diphtheria toxin fusion protein) and certain related assets. Under the terms of agreement, Dr. Reddy's will receive

Dr. Reddy's Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)

HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced that Reddy-Lenalidomide, a generic equivalent to Revlimid® (lenalidomide) capsules, is approved by Health Canada and has been launched in the Canadian market. Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada. “Our launch of Reddy

Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, 5 mg/2.5 mg, a therapeutic equivalent generic version of Librax® (chlordiazepoxide hydrochloride and clidinium bromide) approved by the U.S. Food and Drug Administration (USFDA). The Librax® bran

Dr. Reddy's Laboratories Announces the Launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP in the U.S. Market

Bausch Health Companies Inc

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter known as “Dr. Reddy's”), announced today that it has entered into a definitive asset purchase agreement, pursuant to which Dr. Reddy's will sell its U.S. and Canada territory rights for ELYXYB (celecoxib oral solution) 25 mg/mL, to BioDelivery Sciences International, Inc. (BDSI). Under the terms of agreement, Dr.Reddy's will receive U.S.$6 mill

Dr. Reddy's Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg/mL

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the re-launch of over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Aleve®, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA). “The re-launch of Dr. Reddy's Naproxen Sodium Tablets, 220 mg (OTC), is an impo

Dr. Reddy's Announces the Re-Launch of Over-the-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve® in the U.S. Market

Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q1 2021 Results - Earnings Call Transcript

News for Dr. Reddy's Labs Stock (RDY)